General discussion, page-13360

First 13360 Last

Share
Profile

Follow
MickeyMantle536

933 Posts.

1446

05/04/22

22:03

Post #: 60671720
Share

Originally posted by KingHoves ↑

Ok so from the last quarterly IHL-216A for Concussion and Traumatic Brain Injury is expected to be done, hopefully results soon
and on track

For IHL-675A multi-use drug candidate for Lung Inflammation, Rheumatoid Arthritis, and Inflammatory Bowel Disease, trial should have begun Q4 2021

Results must be due soon based on this:

For IHL-42X for Obstructive Sleep Apnoea the Company has been granted a pre-IND meeting with FDA on May 11. Planning commences for pivotal clinical trials to commence after opening an IND with FDA. So should get feedback this quarter.

For Psilocybin-assisted Psychotherapy for General Anxiety Disorder (Psi-GAD). As per the last quarterly therapist training for the phase 2a trial assessing psilocybin-assisted therapy for Generalised Anxiety Disorder is completed; patient recruitment to commence imminently. So probably not much on this until Q3?

Also - aren't we waiting on a second psychedelics trial to be announced? See here

And they need to explain to us what this acquisition is all about

Plenty of fish to fry in Q2 2022

Expand

The 2nd psychedelics program has been announced, 3 March 2022.

VR + psychedelics via Monash University with exclusive, global license in perpetuity. The technology is already developed and operational so this is the real deal.

Dr Paul Liknaitzky will be head researcher along with Professor Murat Yucel who is a Director of Brain Park at Monash.

The targeted conditions are anxiety disorders.

As you said, plenty of “fish to fry”…

IHL Price at posting: 51.0¢ Sentiment: Buy Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce's R327 found effective against E.coli during clinical trial

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

3DP

Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom